View from above...
So back in October, Intellicell hires 2 investment bankers and simultaneously, the cd holders convert and send this to no bid. Is it possible that IND funding is lined up and Cd holders became aware via first right of refusal. Collectively, this goes dark as they all await execution.
Meanwhile, there is this pre-IND for OA which presumably is dialogue with FDA on how to move forward. Surely the new ultrasonic reactor is in response to FDA concerns, likely over safety of manufacturing the stem cells. This initial protocol development is probably key to launching a dozen other INDs discussed with prominent medical over the past year+.
Money would likely wait over this protocol development. Possibly why this remains dark.
Clearly though they were gearing up.., James Hoch engaged, multiple PRs issued, birdies chirping, etc.. Yet the handling of Hoch is clearly a sign of delay.
What could cause delay? FDA discussions, issues with new reactor, etc. I think the focus must be safety to then have the ability to launch a stream of INDs. No way effectiveness clinicals have even begun, so it must be hung up in the extraction and safety aspects, which given the process and demonstrated successes of past, I think this can be resolved and soon..
Anyone have thoughts on this perspective???
AI
